The ophthalmology drugs market covers drugs that are used in the treatment of eye-related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular degeneration. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax. The market numbers in this briefing cover pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.
Read the report at
The ophthalmic devices market is valued at nearly $31 billion in 2017 due to prevalence of eye conditions such as age-related degeneration, diabetic retinopathy and glaucoma.
North America was the largest geographic region, accounting for almost thirty-percent of the global market.
The ophthalmic devices market in The Business Research Company’s report is segmented into antiglaucoma drugs, dry eye medication, and other ophthalmological drugs.
Download a sample of the report at
The USA was the largest country, accounting for near about thirty percent share of the global ophthalmic devices market in 2017. This is due to high per capita healthcare expenditure and increasing geriatric population in the country. The USA was followed by Germany and Japan.
The top five competitors in the market are Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc., Valeant Pharmaceuticals Intl Inc., and Bayer AG. Novartis AG was the biggest player in the market 2017. It is a multinational pharmaceutical company that develops, manufacture and markets healthcare products. The company is headquartered in Basel, Switzerland.
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: [email protected]